BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

814 related articles for article (PubMed ID: 9380065)

  • 21. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
    Pappert EJ; Germanson T;
    Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of cervical dystonia with botulinum toxin.
    Jankovic J
    Mov Disord; 2004 Mar; 19 Suppl 8():S109-15. PubMed ID: 15027062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to botulinum toxin F in seronegative botulinum toxin A--resistant patients.
    Greene PE; Fahn S
    Mov Disord; 1996 Mar; 11(2):181-4. PubMed ID: 8684389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An open-label, sequential dose-escalation, safety, and tolerability study of rimabotulinumtoxinb in subjects with cervical dystonia.
    Chinnapongse R; Pappert EJ; Evatt M; Freeman A; Birmingham W
    Int J Neurosci; 2010 Nov; 120(11):703-10. PubMed ID: 20942584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum toxin treatment of lateral axial dystonia in Parkinsonism.
    Bonanni L; Thomas A; Varanese S; Scorrano V; Onofrj M
    Mov Disord; 2007 Oct; 22(14):2097-103. PubMed ID: 17685467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia.
    Berman B; Seeberger L; Kumar R
    Mov Disord; 2005 Feb; 20(2):233-7. PubMed ID: 15455449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Safety and tolerance of single-dose botulinum toxin Type A treatment in 204 patients with spasticity and localized associated symptoms. Austrian and German botulinum toxin A spasticity study group].
    Wissel J; Müller J; Heinen F; Mall V; Sojer M; Ebersbach G; Poewe W
    Wien Klin Wochenschr; 1999 Oct; 111(20):837-42. PubMed ID: 10586488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The clinical usefulness of botulinum toxin type A for spasmodic torticollis and facial spasm].
    Mezaki T; Kaji R; Kimura J; Osame M; Mizuno Y; Hirayama K; Maruyama S; Iwata M; Kanazawa I; Kinoshita M
    No To Shinkei; 1995 Aug; 47(8):749-54. PubMed ID: 7546919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.
    Figgitt DP; Noble S
    Drugs; 2002; 62(4):705-22. PubMed ID: 11893235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Botulinum A toxin treatment in spasmodic torticollis: report of 56 patients.
    Poungvarin N; Viriyavejakul A
    J Med Assoc Thai; 1994 Sep; 77(9):464-70. PubMed ID: 7706965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
    Brin MF; Lew MF; Adler CH; Comella CL; Factor SA; Jankovic J; O'Brien C; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
    Neurology; 1999 Oct; 53(7):1431-8. PubMed ID: 10534247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A double-blind comparative study to evaluate the efficacy and safety of NerBloc® (rimabotulinumtoxinB) administered in a single dose to patients with cervical dystonia].
    Kaji R; Shimizu H; Takase T; Osawa M; Yanagisawa N
    Brain Nerve; 2013 Feb; 65(2):203-11. PubMed ID: 23399677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extensor truncal dystonia: successful treatment with botulinum toxin injections.
    Comella CL; Shannon KM; Jaglin J
    Mov Disord; 1998 May; 13(3):552-5. PubMed ID: 9613753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The position of the head in space: a kinematic analysis in patients with cervical dystonia treated with botulinum toxin.
    Albani G; Bulgheroni MV; Mancini F; Mauro A; Fundarò C; Pacchetti C; Sandrini G; Nappi G
    Funct Neurol; 2001; 16(2):135-41. PubMed ID: 11495419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum toxin type B for cervical dystonia.
    Marques RE; Duarte GS; Rodrigues FB; Castelão M; Ferreira J; Sampaio C; Moore AP; Costa J
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD004315. PubMed ID: 27176573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of resistance to botulinum toxin type A in patients with torticollis.
    Greene P; Fahn S; Diamond B
    Mov Disord; 1994 Mar; 9(2):213-7. PubMed ID: 8196686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
    Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
    Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke.
    Jahangir AW; Tan HJ; Norlinah MI; Nafisah WY; Ramesh S; Hamidon BB; Raymond AA
    Med J Malaysia; 2007 Oct; 62(4):319-22. PubMed ID: 18551937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A.
    Greene PE; Fahn S
    Mov Disord; 1993 Oct; 8(4):479-83. PubMed ID: 8232357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay.
    Brin MF; Comella CL; Jankovic J; Lai F; Naumann M;
    Mov Disord; 2008 Jul; 23(10):1353-60. PubMed ID: 18546321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.